Keywords: sales, up, sanofi-synthelabo, 1st, half, france-based, drugmaker
Sales up 14% at Sanofi-Synthelabo in 1st half
Article | 28 July 2003
France-based drugmaker Sanofi-Synthelabo has reported a 14.4% increase in sales (on a comparable basis) to 3.90 billion euros ($3.74 billion) for the first ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
